15 Must-Read Books for Oncologists and Science Enthusiasts

Slideshow

We present a summer reading list of 15 must-reads that cover the history of genes and cancer, the link between so-called junk DNA and disease, uncertainty in medicine, and more.

Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
5 experts in this video
5 experts in this video
Related Content
The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting

Russ Conroy
March 13th 2025
Article

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

ONCOLOGY Staff
March 13th 2025
Article

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.

Considerations for Equity and Regulations for AI Tools in Oncology

Roman Fabbricatore
March 12th 2025
Article

Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.

Vepdegestrant Meets PFS Primary End Point in ESR1m ER+/HER2– Breast Cancer

Roman Fabbricatore
March 12th 2025
Article

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.